{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:21:55Z","timestamp":1771456915435,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,4,5]],"date-time":"2002-04-05T00:00:00Z","timestamp":1017964800000},"content-version":"vor","delay-in-days":704,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta\u2010lactam antibiotics for serious Gram\u2010negative infections. Severe melioidosis (<jats:italic>Burkholderia pseudomallei<\/jats:italic> infection) carries a mortality of 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime <jats:italic>vs<\/jats:italic> intermittent bolus dosing in septicaemic melioidosis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40\u2003mg kg<jats:sup>\u22121<\/jats:sup> 8\u2003hourly by bolus injection or 4\u2003mg kg<jats:sup>\u22121<\/jats:sup>\u2003h<jats:sup>\u22121<\/jats:sup> by constant infusion following a 12\u2003mg kg<jats:sup>\u22121<\/jats:sup> priming dose to perform estimation of pharmacokinetic and pharmacodynamic parameters.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for <jats:italic>B. pseudomallei<\/jats:italic> of whom 12 (60%) died. The median MIC<jats:sub>90<\/jats:sub> of <jats:italic>B. pseudomallei<\/jats:italic> was 2\u2003mg l<jats:sup>\u22121<\/jats:sup>, giving a target concentration <jats:italic>C<\/jats:italic><jats:sub>T<\/jats:sub>, of 8\u2003mg l<jats:sup>\u22121<\/jats:sup>. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half\u2010lives of ceftazidime were 0.468 (0.241\u20130.573) l\u2003kg<jats:sup>\u22121<\/jats:sup>, 0.058 (0.005\u20130.159) l\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003h<jats:sup>\u22121<\/jats:sup> and 7.74 (1.95\u201344.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (<jats:italic>r<\/jats:italic>\u2003=\u20030.71; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) and there was no evidence of significant nonrenal clearance.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Simulations based on these data and the ceftazidime sensitivity of the <jats:italic>B. pseudomallei<\/jats:italic> isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8\u2003h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure which is common in these patients is Clearance =<jats:italic>k<\/jats:italic>* creatinine clearance where <jats:italic>k<\/jats:italic>\u2003=\u20030.072. Calculation of a loading dose gives median (range) values of loading dose, <jats:italic>D<\/jats:italic><jats:sub>L<\/jats:sub> of 3.7\u2003mg kg<jats:sup>\u22121<\/jats:sup> (1.9\u20134.6) and infusion rate I\u2003=\u20030.46\u2003mg kg h<jats:sup>\u22121<\/jats:sup> (0.04\u20131.3) (which equals 14.8\u2003mg kg<jats:sup>\u22121<\/jats:sup> day<jats:sup>\u22121<\/jats:sup>). A nomogram for adjustment in renal failure is given.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2000.00179.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:38:16Z","timestamp":1047357496000},"page":"445-452","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetic\u2010pharmacodynamic evaluation of ceftazidime continuous infusion <i>vs<\/i> intermittent bolus injection in septicaemic melioidosis"],"prefix":"10.1111","volume":"49","author":[{"given":"B. J.","family":"Angus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Suputtamongkol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Wuthiekanun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Chaowagul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.3.281"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.399"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.3.289"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000138851"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.931"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.309"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900413"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.5.890"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90768-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.5.846"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.3.295"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.1.145"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.6.1498"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-33-2-121"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.6.645"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(95)90104-3"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542421"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.3.343"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05427.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/23.5.1082"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198529020-00002"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.6.892"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548909035704"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.5.638"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03337.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.125"},{"key":"e_1_2_6_31_2","first-page":"354","article-title":"Pharmacokinetics of ceftazidime and netilimicin in patients with sepsis","volume":"25","author":"Ganzinger U","year":"1987","journal-title":"Int J Pharmacol Ther Toxicol"},{"key":"e_1_2_6_32_2","first-page":"457","article-title":"Ceftazidime in the treatment of Pseudomonas infections in intensive\u2010care patients","volume":"24","author":"Rondanelli R","year":"1986","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709707"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.464"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","unstructured":"Prediction by APACHE ScoreLancet1986;ii:286\u2013287.","DOI":"10.1016\/S0140-6736(86)92106-9"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.1.95"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/15.3.365"},{"key":"e_1_2_6_38_2","unstructured":"RowlandM TozerT.Clinical pharmacokinetics: Concepts and applications 1st edn.Philadelphia London: Lea & Febiger1989."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6701(90)90076-Z"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.3.298"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.2.269"},{"key":"e_1_2_6_42_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/AAC.40.3.691","article-title":"Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram\u2010negative infections","volume":"40","author":"Benko AS","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.2053"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1985.tb03424.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ajhp\/55.2.145","article-title":"Continuous infusion of ceftazidime with an elastomeric infusion device","volume":"55","author":"Couldry R","year":"1998","journal-title":"Am J Health Syst Pharm"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00179.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00179.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2000.00179.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T10:43:22Z","timestamp":1698576202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2000.00179.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1046\/j.1365-2125.2000.00179.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00179.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}